close
close

Bronstein, Gewirtz & Grossman LLC announces that investors with significant losses at Biogen Inc. have the opportunity to file a class action lawsuit!

NEW YORK, May 30, 2024 /PRNewswire/ – Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Biogen Inc. (“Biogen Inc.” or “the Company”) (NASDAQ: BIIB) and certain of its officers.

Class definition:

The aim of this action is to assert claims for damages against the defendants for allegedly Violations of the federal securities laws on behalf of all persons and entities who purchased or otherwise acquired Biogen Inc. securities between February 3, 2022 And February 13, 2024inclusive (the “Litigation Period”). These investors are encouraged to join this case by visiting the Company’s website: bgandg.com/BIIB.

Case details:

The complaint claims that throughout the Class Period, Defendants made materially false and misleading statements about the Company’s business, operations and compliance policies. In particular, the complaint claims that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Biogen overstated its efforts to improve its transparency, corporate governance and compliance controls and procedures and the effectiveness of those controls and procedures; (2) Biogen accordingly maintained inadequate compliance controls and procedures in connection with its foreign operations; (3) Biogen and/or its employees engaged in unlawful or otherwise inappropriate conduct in several countries; (4) the foregoing exposed the Company to an increased risk of governmental and/or regulatory scrutiny and enforcement actions, as well as significant legal, financial and reputational harm; (5) Biogen overstated the strength of its AD-related product portfolio, including the Company’s and Eisai’s efforts and success in bringing Leqembi to market and providing access to Leqembi; (6) Biogen also understated the negative impact of the Reata acquisition on its fiscal 2023 non-GAAP diluted earnings per share; (7) all of the foregoing would likely have a material adverse effect on Biogen’s 2023 results; and (8) as a result, the Company’s public statements were materially false and misleading at all relevant times.

What’s next?

A class action lawsuit has already been filed. If you would like to view a copy of the lawsuit, you can visit the company’s website: bgandg.com/BIIB or you can contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Millerof Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you have suffered a loss with Biogen Inc., you have until July 22, 2024to request that the Court appoint you as lead plaintiff. Your ability to share in any compensation is not dependent on your serving as lead plaintiff.

There are no costs for you

We represent investors in class action lawsuits on a contingency basis, meaning we ask the court to reimburse us for our expenses and attorney fees (usually a percentage of the total award) only if we win.

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm representing investors in securities Fraud Class action lawsuits and shareholder litigation. Our firm has recovered hundreds of millions of dollars for investors across the country.

Attorney advertising. Past results do not guarantee similar results.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Nathan Miller

332-239-2660 | (email protected)

Never miss a story from Bronstein, Gewirtz & Grossman, LLC again.